Back to School: How biopharma can reboot drug development. Access exclusive analysis here

XP13512: Phase IIa started

XenoPort began a double-blind, placebo-controlled, crossover Phase

Read the full 74 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE